Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 22 | -0.87
Decreased by
-117.50%
|
-0.77
Decreased by
-12.99%
|
Aug 8, 22 | -0.81
Decreased by
-131.43%
|
-0.63
Decreased by
-28.57%
|
May 9, 22 | -0.60
Decreased by
-25.00%
|
-0.71
Increased by
+15.49%
|
Nov 11, 21 | -0.61
Decreased by
-69.44%
|
-0.48
Decreased by
-27.08%
|
Aug 12, 21 | -0.40
Increased by
+90.93%
|
-0.43
Increased by
+6.98%
|
May 17, 21 | -0.35
Increased by
+97.73%
|
-0.41
Increased by
+14.63%
|
Mar 18, 21 | -0.48 | -0.35
Decreased by
-37.14%
|
Nov 12, 20 | -0.36 | -0.36 |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-35.32 M
Decreased by
-43.78%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-32.92 M
Decreased by
-102.29%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-24.53 M
Decreased by
-72.95%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
-100.00%
|
-83.50 M
Decreased by
-344.79%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-24.57 M
Decreased by
-141.29%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
-100.00%
|
-16.27 M
Decreased by
-43.62%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
-100.00%
|
-14.19 M
Decreased by
-160.08%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 1.18
Decreased by
-100.00%
|
-18.77 M
Decreased by
-141.81%
|
Decreased by
-1.59 B%
Decreased by
-248.15 M%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.